Author: Kopecky-Bromberg, Sarah A.; Palese, Peter
Title: Recombinant Vectors as Influenza Vaccines Cord-id: pnl1acrj Document date: 2009_6_15
ID: pnl1acrj
Snippet: The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the a
Document: The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.
Search related documents:
Co phrase search for related documents- acute respiratory infection and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute respiratory infection and adenovirus infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute respiratory infection and adenovirus vector: 1, 2, 3, 4
- acute sars cov respiratory syndrome virus and adaptive immune response: 1, 2, 3
- acute sars cov respiratory syndrome virus and adenovirus vector: 1
- adaptive immune response and adenovirus infection: 1
- adaptive immune response and adenovirus vector: 1, 2
Co phrase search for related documents, hyperlinks ordered by date